Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cyclacel Pharmaceuticals advances Phase II study with promising results and financial boost

Cyclacel Pharmaceuticals made significant progress in Q1 2024 with financing, study advancements, and expense management.
While facing financial challenges and study enrollment timelines, the company remains focused on key milestones and opportunities.
The company's strengths lie in promising study results, solid cash position, and proactive approach to clinical development.
Overall, Cyclacel Pharmaceuticals is poised for growth and value creation in 2024 through strategic advancements.

Cyclacel Pharmaceuticals progresses with fadra, poised for oncology market growth

Cyclacel's fadra program is showing clinical promise and cost efficiency, supported by a stable financial position.
Clear communication of enrollment targets and data disclosure timelines is crucial for maintaining investor confidence.
Optimism for upcoming milestones and engagement opportunities position Cyclacel well for potential growth in the oncology market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals Inc 6 % Conv Pfd Shs

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2021 financial results on Monday, March 28, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the 2022 BIO CEO & Investor Conference on February 14-17, 2022.

Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel's business and the Company will be available for virtual meetings during the conference. In addition, Mr. Rombotis will participate in a Biotech Showcase Workshop, entitled, “Outsmarting Cancer: Next Generation Therapies”.

Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript

Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update on Wednesday, November 10, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September.

Cyclacel Pharmaceuticals Presenting at Three Conferences in September

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript

- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET -

Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

-Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study- -Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study-

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann's Virtual 2021 Healthcare Conference held July 13-14, 2021. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel's business followed by an analyst-led fireside chat.

Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call Transcript

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -  - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -  - Following Recent Financing, Cash Runway Extended to Early 2023 -  - Conference Call Scheduled May 12, 2021 at 4:30 p.m. ET -

Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a business update on Wednesday, May 12, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced underwritten public offering of 2,078,214 shares of its common stock, offered at a price of $7.00 to the public, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares. The gross proceeds to the Company from this offering are approximately $14.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Existing and new institutional investors participated in the offering.

Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT). Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors during the event.

Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will raise gross proceeds of approximately $12.65 million.

Cyclacel Pharmaceuticals Presses Capital Raise Button

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offering of 1,807,143 shares of its common stock, offered at a price of $7.00 to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 271,071 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about March 16, 2021, subject to customary closing conditions. The gross proceeds to the Company from this offering are expected to be approximately $12.65 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. This amount assumes no exercise of the underwriters' option.

Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Cyclacel.

Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021 BIO CEO & Investor Digital Conference. The conference is taking place online between February 16-18, 2021 and a prerecorded presentation by Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00AM ET via the virtual conference link.

Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures –

News for Cyclacel Pharmaceuticals Stock (CYCC)